This paper details a design optimization on a hardware accelerator for an on-board real-time SAR imaging system using the Backprojection algorithm, focusing on algorithm-specific approximations intended to reduce the overhead introduced by intensive functions such as the square root, sine, and cosine functions. The main novelty of this work is that new approximations were investigated so that the final image retains high quality regardless of the error in the approximation function. This paper revisits existing approximation methods, such as linear interpolation, polynomial approximation using the Vandermonde matrix, and Chebyshev polynomials, and compares their performance on the algorithm. Results demonstrate that it is possible to maintain the image quality with an SSIM above 0.99 with less 93% LUTs for the square root and less 88% LUTs for the sine and cosine functions using polynomial approximation with the Vandermonde matrix when compared to the HLS baseline functions.

Patients with polycythemia vera (PV) are at increased risk of thrombosis and hemorrhages. Although hydroxyurea (HU) has been the frontline therapy for patients at high-risk of vascular complications, about 25% of patients develop resistance/intolerance to this therapy. The aim of this non-interventional, multicenter cohort study was to understand the clinical characteristics and HU treatment response of Portuguese PV patients. HU resistance/intolerance was defined according to adjusted European LeukemiaNet (ELN) criteria. 134 PV patients with a mean disease duration of 4.8±5.0 years were included and followed up for 2 years. At baseline, most patients were ≥60 years old (83.2%), at high risk for thrombotic events (87.2%), and receiving HU therapy (79.1%). A total of 10 thrombotic events and 8 hemorrhagic events were reported, resulting in a 5-year probability of thrombo-hemorrhagic events of 17.2%. Hematocrit (p=0.007), hemoglobin (p=0.012) and MPN10 symptom score (12.0±11.6 vs 10.3±9.1; p=0.041) decreased significantly at the 24-month visit compared to baseline. Overall, 75.9% of patients met at least one of the adjusted ELN criteria for HU resistance. 14.4% of patients remained on HU throughout the study. The results from this real-world study may help identify the subset of patients at higher risk of disease sequelae who may benefit from earlier second-line treatment.